Neuroendocrine Assessment of Dopaminergic Function during Antidepressant Treatment in Major Depressed Patients.
antidepressant
apomorphine
cortisol
dexamethasone
dopamine
remission
Journal
Brain sciences
ISSN: 2076-3425
Titre abrégé: Brain Sci
Pays: Switzerland
ID NLM: 101598646
Informations de publication
Date de publication:
26 Mar 2021
26 Mar 2021
Historique:
received:
26
01
2021
revised:
09
03
2021
accepted:
23
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
The effects of antidepressants on dopamine (DA) receptor sensitivity in the mesolimbic-hypothalamic system have yielded contradictory results. The postsynaptic DA receptor function was evaluated by the cortisol response to apomorphine (APO; 0.75 mg SC) in 16 drug-free DSM-5 major depressed inpatients and 18 healthy hospitalized control (HC) subjects. Cortisol response to the dexamethasone suppression test (DST) was also measured. After two and four weeks of antidepressant treatment (ADT), the DST and APO test were repeated in all patients. Cortisol response to APO (∆COR) was not influenced by the hypothalamic-pituitary-adrenal (HPA) axis activity, as assessed by the DST. Pre-treatment ∆COR values did not differ significantly between patients and HCs. During ADT, ∆COR values were lower than in HCs at week 2 and 4. After four weeks of treatment, among the eight patients who had blunted ∆COR values, seven were subsequent remitters, while among the eight patients who had normal ∆COR values, seven were non-remitters. Considering the limitations of our study, the results suggest that following chronic ADT, the desensitization of postsynaptic DA receptors connected with the regulation of the HPA axis at the hypothalamic level is associated with clinical remission. These results could reflect increased DA levels in the mesolimbic pathway.
Identifiants
pubmed: 33810562
pii: brainsci11040425
doi: 10.3390/brainsci11040425
pmc: PMC8065982
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Brain Res. 1996 Oct 28;738(1):60-6
pubmed: 8949928
Curr Med Res Opin. 1982;8(3):150-3
pubmed: 7128188
Psychoneuroendocrinology. 2001 Oct;26(7):689-96
pubmed: 11500250
Biol Psychiatry. 1994 Jan 15;35(2):128-32
pubmed: 8167208
J Neural Transm (Vienna). 1999;106(2):197-211
pubmed: 10226939
Front Psychiatry. 2020 Sep 18;11:533872
pubmed: 33101075
Front Neurosci. 2010 Nov 19;4:192
pubmed: 21151361
Int Rev Cell Mol Biol. 2018;339:63-91
pubmed: 29776605
Neuropharmacology. 1992 Jul;31(7):671-8
pubmed: 1328919
Biol Psychiatry. 2018 Oct 15;84(8):563-573
pubmed: 30041971
J Psychopharmacol. 2011 Oct;25(10):1329-36
pubmed: 20829308
J Affect Disord. 2005 May;86(1):37-45
pubmed: 15820269
Prog Neuropsychopharmacol Biol Psychiatry. 2000 Feb;24(2):207-25
pubmed: 10800744
Mol Psychiatry. 2010 Mar;15(3):237-49
pubmed: 19704408
J Psychopharmacol. 2000 Jun;14(2):152-6
pubmed: 10890309
Psychoneuroendocrinology. 2013 Aug;38(8):1213-9
pubmed: 23684480
J Affect Disord. 2003 Sep;76(1-3):121-5
pubmed: 12943941
Biol Psychiatry. 2007 Jan 15;61(2):145-53
pubmed: 16934770
Eur J Pharmacol. 1997 Mar 19;322(2-3):123-7
pubmed: 9098678
Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(2-3):117-64
pubmed: 3290992
Psychoneuroendocrinology. 2005 Oct;30(9):839-45
pubmed: 15964147
World J Biol Psychiatry. 2013 Jul;14(5):334-85
pubmed: 23879318
Semin Nucl Med. 1978 Oct;8(4):283-98
pubmed: 112681
Nature. 1980 Oct 2;287(5781):451-4
pubmed: 7432470
Synapse. 2007 Feb;61(2):72-7
pubmed: 17117425
Pharmacol Res Commun. 1980 Jun;12(6):619-24
pubmed: 7403234
Am J Psychiatry. 2006 Sep;163(9):1594-602
pubmed: 16946186
Arch Gen Psychiatry. 1991 Sep;48(9):851-5
pubmed: 1929776
Neuropsychobiology. 1995;32(1):19-22
pubmed: 7566518
Arch Gen Psychiatry. 2007 Mar;64(3):327-37
pubmed: 17339521
Dialogues Clin Neurosci. 2006;8(2):191-206
pubmed: 16889105
J Clin Pharm Ther. 2007 Oct;32(5):415-28
pubmed: 17875106
J Pharmacol Exp Ther. 2002 Nov;303(2):791-804
pubmed: 12388666
Lancet. 2018 Apr 7;391(10128):1357-1366
pubmed: 29477251
Eur J Pharmacol. 2000 Sep 29;405(1-3):365-73
pubmed: 11033341
Psychopharmacology (Berl). 1996 Aug;126(4):277-80
pubmed: 8878342
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
Neuroimage. 2000 Oct;12(4):452-65
pubmed: 10988039
Cell Res. 2009 May;19(5):612-24
pubmed: 19274064
J Psychiatr Res. 2019 May;112:18-22
pubmed: 30836201
Acta Psychiatr Scand. 2019 Aug;140(2):116-125
pubmed: 31111467
Psychoneuroendocrinology. 2006 Aug;31(7):876-88
pubmed: 16769179
Psychol Med. 1997 Nov;27(6):1247-56
pubmed: 9403896
Neuropharmacology. 2014 Jul;82:28-40
pubmed: 24657149
Int J Neuropsychopharmacol. 2004 Dec;7(4):431-9
pubmed: 15315717
Dialogues Clin Neurosci. 2002 Dec;4(4):417
pubmed: 22033833
J Chem Neuroanat. 2019 Jul;98:97-103
pubmed: 31018158
Psychiatry (Edgmont). 2006 Jul;3(7):42-61
pubmed: 20975817
J Pharmacol Exp Ther. 2010 May;333(2):555-63
pubmed: 20164301
J Clin Psychiatry. 2005 Jun;66(6):670-6
pubmed: 15960558
Biol Psychiatry. 1992 Jul 1;32(1):1-17
pubmed: 1391289
Psychoneuroendocrinology. 1995;20(4):365-75
pubmed: 8532820
Transl Psychiatry. 2014 Jul 15;4:e411
pubmed: 25026323
Psychoneuroendocrinology. 1999 Oct;24(7):695-712
pubmed: 10451906
Psychopharmacology (Berl). 1984;83(4):378-9
pubmed: 6436869
Eur Neuropsychopharmacol. 2017 Oct;27(10):977-986
pubmed: 28870407
Psychopharmacology (Berl). 1996 Jul;126(1):91-4
pubmed: 8853222
Int J Neuropsychopharmacol. 2017 Dec 1;20(12):1036-1046
pubmed: 29106542
BMJ. 1991 Sep 14;303(6803):613-6
pubmed: 1805821
Behav Pharmacol. 2002 Mar;13(2):127-38
pubmed: 11981225
Synapse. 2009 Jan;63(1):1-6
pubmed: 18925655
Clin Ther. 2006 Aug;28(8):1065-1078
pubmed: 16982285
Eur J Pharmacol. 1981 Sep 11;74(2-3):195-206
pubmed: 7198991
Arch Gen Psychiatry. 1984 May;41(5):512-9
pubmed: 6721674
Arch Gen Psychiatry. 1981 Jan;38(1):15-22
pubmed: 7458567